On the stock market since 2023, it operates in the world of health and science. It has 731 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $42.5M. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 14% a year on average.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, RHEPB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RHEPB is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.